Developing a safer E. coli strain for making therapeutic proteins and DNA
Official title: An improved low-endotoxin Clean Genome E. coli strain for production of biological products
Funded at Scarab Genomics, LLC · NIH-11008247 · Data updated 2026-11-12
This study is working on a special type of E. coli that can make important medicines with fewer harmful substances, aiming to create safer and more effective treatments for conditions like cancer and gene therapy.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Scarab Genomics, LLC NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $842,151 |
| NIH project number | 1R44GM156147-01 |
| Project ID | NIH-11008247 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for benefiting from this research include patients requiring gene therapy or cancer treatments that utilize recombinant proteins or plasmid DNA.
✕Less likely to help
Patients who do not require treatments involving recombinant proteins or plasmid DNA may not benefit from this research.
What this research studies
This research focuses on creating a new strain of E. coli that produces therapeutic proteins and plasmid DNA with lower levels of harmful endotoxins. By using advanced genetic techniques, the team aims to enhance the safety and effectiveness of these biological products, which are crucial for treatments like gene therapy and cancer drugs. The project will leverage Scarab Genomics' patented Clean Genome® platform to ensure that the new E. coli strain has improved genetic stability and reduced contamination risks. Patients may benefit from safer and more effective therapies produced using this innovative bacterial strain.
Why it matters
Potential benefit: If successful, this research could lead to the production of safer and more effective therapeutic proteins and DNA for patients.
How similar studies have gone: Previous research has shown success in using genetically modified E. coli strains for producing therapeutic agents, indicating a promising approach.
Where this research is happening
-
Scarab Genomics, LLC
Madison, United States Active
Researchers
- Principal investigator: Frisch, David a — Scarab Genomics, LLC
- Study coordinator: Frisch, David a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.